Browsing by author "Vivanco, Igor"
Now showing items 1-7 of 7
-
A kinase-independent function of AKT promotes cancer cell survival.
Vivanco, I; Chen, ZC; Tanos, B; Oldrini, B; Hsieh, W-Y; et al. (ELIFE SCIENCES PUBLICATIONS LTD, 2014-12-31)The serine-threonine kinase AKT regulates proliferation and survival by phosphorylating a network of protein substrates. In this study, we describe a kinase-independent function of AKT. In cancer cells harboring gain-of-function ... -
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.
Kostaras, E; Kaserer, T; Lazaro, G; Heuss, SF; Hussain, A; et al. (SPRINGERNATURE, 2020-08-18)BACKGROUND: AKT, a critical effector of the phosphoinositide 3-kinase (PI3K) signalling cascade, is an intensely pursued therapeutic target in oncology. Two distinct classes of AKT inhibitors have been in clinical development, ... -
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.
Oldrini, B; Hsieh, W-Y; Erdjument-Bromage, H; Codega, P; Carro, MS; et al. (NATURE PUBLISHING GROUP, 2017-12-11)Transport of macromolecules through the nuclear pore by importins and exportins plays a critical role in the spatial regulation of protein activity. How cancer cells co-opt this process to promote tumorigenesis remains ... -
Inhibitors in AKTion: ATP-competitive vs allosteric.
Lazaro, G; Kostaras, E; Vivanco, I (PORTLAND PRESS LTD, 2020-06-30)Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target. Multiple AKT ... -
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
Stein, S; Zhao, R; Haeno, H; Vivanco, I; Michor, F (PUBLIC LIBRARY SCIENCE, 2018-01-01)Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively ... -
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon, E; Liang, T; Jamin, Y; Walz, S; Kwok, C; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-11-02)The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show ... -
Targeting molecular addictions in cancer.
Vivanco, I (NATURE PUBLISHING GROUP, 2014-11-25)Cancer cells depend on a finite number of critical signals for their survival. Oncogene addiction, that is, the acquired dependence of a cancer cell on the activity of a single oncogenic gene product, has been the basis ...